PeterAlfredLewittMDM.Med.Sc.

PubMed

• Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.
  Stuart H Isaacson, Alberto J Espay, Rajesh Pahwa, Pinky Agarwal, Holly A Shill
  Journal of Parkinson's Disease. 2025-01-29
• The effect of AKT inhibition in α-synuclein-dependent neurodegeneration.
  Bedri Ranxhi, Zoya R Bangash, Zachary M Chbihi, Sokol V Todi, Peter A LeWitt
  Frontiers in Molecular Neuroscience. 2025-01-01
• 1 citations
  Anticholinergic drugs for parkinsonism and other movement disorders.
  Peter A LeWitt, Luke Hong, Mark S Moehle
  Journal of Neural Transmission. 2024-12-01

Journal Articles

• Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease  
  Peter Lewitt, MD, JAMA Neurology
• Double-blind Study of an Actively-transported Levodopa Prodrug, XP21279, in Parkinson Disease  
  LeWitt PA, Huff FJ, Hauser R, Chen D, Lissin D, Cundy K, Mov Disord, 1/1/2014
• Test-retest Reliability of an Objective PD Monitoring System  
  Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP, Parkinsonism Relat Disord, 1/1/2014
• Predicting the Development of Levodopa-induced Dyskinesias: A Presynaptic Mechanism?  
  LeWitt PA, Mouradian MM, Neurology, 1/1/2014
• Norepinephrine Deficiency in Parkinson Disease: The Case for Noradrenergic Enhancement  
  Espay AJ, LeWitt PA, Kaufmann H, Mov Disord, 1/1/2014
• Rotigotine Transdermal System for Long-term Treatment of Patients with Advanced Parkinson's Disease: Results of Two Open-label Extension from CLEOPATRA-PD and PREFER  
  LeWitt PA, Boroojerdi B, Surmann E, Poewe W, on Behalf of the SP516 and SP715 Study Groups, J Neural Transm, 1/1/2013
• Treatment of Patients with Early and Advanced Parkinson's Disease with Rotigotine Transdermal System: Age-relationship to Safety and Tolerability  
  Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B, Parkinsonism Relat Disord, 1/1/2013
• Sustained Efficacy and Safety of Repeated Incobotulinumtoxin A (Xeomin(R)) Injections in Blepharospasm  
  Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A Fernandez HH, for the Xeomin US Blepharospasm Study Group, J Neural Transm, 1/1/2013
• 5-Hydroxykynurenine and Other Biomarkers of Parkinson's Disease Discovered by Metabolomic Analysis  
  LeWitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L, Arizona Parkinson's Disease Consortium, Mov Disord, 1/1/2013
• Tardive Dyskinesia Caused by Tetrabenazine  
  LeWitt PA, Clin Neuropharmacol, 1/1/2013
• Fipamezole in the Treatment of Dyskinesias in Advanced Parkinson Disease (FJORD Study)  
  LeWitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinnonen M, Savola J-M, Neurology, 1/1/2012
• Actively-transported Levodopa Prodrug XP21279: A Study in Patients with Parkinson's Disease Who Experience Motor Fluctuations  
  LeWitt PA, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ, Clin Neuropharmacol, 1/1/2012
• Validity and Reliability of a New Scale for Essential Tremor  
  Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, LeWitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T, Mov Disord, 1/1/2012
• Meta-analysis of Parkinson's Disease: Identification of a Novel Locus, RIT2  
  Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER,..., Ann Neurol, 1/1/2012
• Recent Advances in CSF Biomarkers for Parkinson's Disease  
  LeWitt PA, Parkinsonism Relat Disord, 1/1/2012
• Norepinephrine: The Next Therapeutics Frontier for Parkinson's Disease  
  LeWitt PA, Translational Neurodegeneration, 1/1/2012
• Abnormal Apocrine Secretory Cell Mitochondria in a Huntington Disease Patient  
  Sidiropoulos C, LeWitt PA, Hashimoto K., J Neurol Sci, 1/1/2012
• A Randomized Multicenter Double-blind Clinical Trial of AAV2-GAD Gene Therapy for Advanced Parkinson's Disease  
  LeWitt PA, Rezai AR, Leehey MA, OjemannSG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan..., Lancet Neurol, 1/1/2011
• CSF Xanthine, Homovanillic Acid, And Their Ratio As Biomarkers Of Parkinson's Disease  
  LeWitt PA, Schultz L, Auinger P, Lu M, Parkinson Study Group-DATATOP Study Investigators, Brain Res, 1/1/2011
• Localizing Imbalance in Progressive Supranuclear Palsy: Is the Thalamus the "Fall Guy"?  
  Sidiropoulos C, LeWitt PA, Neurology, 1/1/2011
• Is Levodopa Toxic? - Insights from a Brain Bank  
  LeWitt PA, Dubow J, Singer C, Neurology, 1/1/2011
• Maternal Inheritance and Mitochondrial DNA Variants in Familial Parkinson's Disease  
  Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T, Parkinson Study Group-PROGENI Investigators (including PA LeWitt)., BMC Med Genet, 1/1/2010
• Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease  
  Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B, NINDS NET-PD Investigators (including PA LeWitt)., Mov Disord, 1/1/2010
• Relief of Parkinsonism and Dyskinesia: One and the Same Mechanism?  
  LeWitt PA, Neurology, 1/1/2010
• Mutations in GBA Are Associated with Familial Parkinson Disease Susceptibility and Age at Onset  
  Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators (in..., Neurology, 1/1/2009
• Join now to see all

Books/Book Chapters

• Medication-Induced Movement Disorders 
  Chapter: Drug-induced Tremors 
  LeWitt PAEditors: Friedman JH.Cambridge Press, London (U.K.)2014
• Chorea: Causes and Management 
  Chapter: A Clinician's Approach to Chorea 
  Page 1.0 - 10.0LeWitt PAEditors: Micheli FE, LeWitt PA.Springer Clinical Medicine, London (U.K.)2014
• Chorea: Causes and Management 
  Editors: Micheli FE, LeWitt PA.Springer Clinical Medicine, London (U.K.)2014
• Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future, Advances in Predictive, Preventive, and Personalized Medicine 
  Chapter: An Update on CSF Biomarkers of Parkinson's Disease 
  Page 161.0 - 184.0LeWitt PA, Huber BR, Zhang JEditors: Mandel S.Springer, Dordrecht2013
• Encyclopedia of Movement Disorders 
  Chapter: Dopaminergic Agonists in Parkinson's Disease 
  Page 332.0 - 336.0LeWitt PAEditors: Kompoliti K, Verhagen Metman L.Academic Press, Oxford2010
• Pharmacotherapy in Primary Care 
  Chapter: Parkinson's Disease 
  Page 195.0 - 201.0LeWitt PA, Berchou RCEditors: Linn WD, Wofford MR, O'Keefe ME, Posey LM.2009
• Parkinson's Disease and Movement Disorders 
  Chapter: Neurologic Aspects of Wilson's Disease: Clinical Manifestations and Treatment 
  Page 254.0 - 270.0LeWitt P, Pfeiffer REditors: Jankovic J, Tolosa E.Lippincott Williams & Wilkins, PhiladelphiaEdition Fift,2006
• Enfermedad de Parkinson y trastornos relacionados 
  Chapter: Agonistas dopaminergicos en la enfermedad de Parkinson 
  Page 237.0 - 256.0LeWitt P, Zuniga Ramirez CEditors: Micheli F.Medica Panamericana, Buenes AiresEdition 2.0,2006
• Oxidative Stress and Neuroprotection 
  Chapter: Neuroprotection for Parkinson's Disease 
  LeWitt PA2006
• Neurodegenerative Diseases: Neurobiology, Pathogenesis, and Therapeutics 
  Chapter: Neurological Aspects of Wilson's Disease 
  Page 890.0 - 905.0LeWitt PA, Brewer GJEditors: Beal F, Lang A, Ludolph AC.Cambridge University Press, London2005
• Therapy of Parkinson's Disease 
  Chapter: New and Experimental Treatments 
  Page 491.0 - 505.0LeWitt PAEditors: Pahwa R, Lyons KE, Koller WC.Marcel Dekker, New YorkEdition Thir,2004
• Drug-induced Movement Disorders 
  Chapter: Involuntary Movements Caused by Levodopa 
  Page 259.0 - 278.0LeWitt PA, Mihaila DEditors: Sethi K.Marcel Dekker, New York2004
• Neurological Therapeutics: Principles and Practice 
  Chapter: Wilson's Disease 
  Page 2671. - 2676.LeWitt PAEditors: Noseworthy JH.Martin Dunitz, London2003
• Encyclopedia of the Neurological Sciences 
  Chapter: Clonus 
  Page 728.0 - 729.0LeWitt PA, Mihaila DEditors: Aminoff M, Daroff RB.Academic Press, New York2003
• Office Practice of Neurology 
  Chapter: Improving Responses to Levodopa 
  Page 749.0 - 756.0LeWitt PAEditors: Samuels MA, Feske SK.Edition 2nd,2003
• Parkinson's Disease: Diagnosis and Clinical Management 
  Chapter: Tobacco Smoking, Nicotine, and Neuroprotection 
  Page 519.0 - 529.0LeWitt PAEditors: Factor SA, Weiner WJ.Demos, New York2002
• Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician 
  Chapter: Parkinson's Disease: Etiologic Considerations 
  Page 91.0 - 100.0LeWitt PAEditors: Ahlskog JE, Adler CA.Humana Press, New York2000
• Parkinson's Disease: The Treatment Options 
  Chapter: Extending the Action of Levodopa's Effects 
  Page 141.0 - 158.0LeWitt PAEditors: LeWitt PA, Oertel WH.Martin Dunitz Publishers, London1999
• Parkinson's Disease: The Treatment Options 
  Chapter: Pharmacology of Dopaminergic Agonists for Parkinson's Disease 
  Page 159.0 - 186.0LeWitt PAEditors: LeWitt PA, Oertel WH.Martin Dunitz Publishers, London1999
• Parkinson's Disease: The Treatment Options 
  Editors: LeWitt PA, Oertel WH.Martin Dunitz Publishers, London1999
• Textbook of Clinical Neurology 
  Chapter: Body Fluid and Tissue Analysis 
  Page 458.0 - 474.0LeWitt PA, Kupsky W, Ferrante MA, Gabern J, Nikhar N, Tselis ACEditors: Goetz CG, Pappert EJ.WB Saunders, Philadelphia1999
• Parkinson's Disease and Related Movement Disorders 
  Chapter: Neurological Aspects of Wilson's Disease: Clinical and Treatment Considerations 
  Page 377.0 - 399.0LeWitt PA, Pfeiffer R.Editors: Jankovic J, Tolosa E.WB Saunders, PhiladelphiaEdition Thir,1998
• Pick's Disease and Pick Disorder 
  Chapter: The Movement Disorders of Corticobasal Degeneration 
  Page 105.0 - 120.0LeWitt PAEditors: Kertesz A, Munoz DG.JB Wiley & Sons, Philadelphia1998
• Enfermedad de Parkinson y trastornos relacionados 
  Chapter: Agonistas dopaminergicos para el tratamiento de la enfermedad de Parkinson 
  Page 137.0 - 151.0LeWitt PAEditors: Micheli FE.Panamerica Editorial Medica, Bogota1997
• Baillière's Clinical Neurology 
  Chapter: New Options For The Treatment Of Parkinson's Disease 
  Page 109.0 - 123.0LeWitt PAEditors: Quinn NP.Baillière Tindall, London1997
• Join now to see all

Abstracts/Posters

• Accordion Pill Carbidopa/Levodopa (AP CD/LD) for Treatment of Advanced Parkinson's Disease (PD).
  LeWitt PA, Giladi N, Gurevich T, Shabtai H, Djaldetti R, Roizen N, Hassin-Baer S, Cohen O, Yahalom G, Schlesinger I, Nassar M, Milo R, Anca M, Farkas P, Lamp Y, Navon ..., Mov Disord, 1/1/2014
• Incisionless Thalamotomy for Essential Tremor by MR-guided Focused Ultrasound -randomized, Sham-controlled Trial
  Ondo W, LeWitt P, Elias WJ, Mov Disord, 1/1/2014
• A Novel Mutation Resulting in a Mild Phenotype of Spinocerebellar Ataxia 13
  Herrema H, Sidiropoulos C, LeWitt P, Mov Disord, 1/1/2014
• Baseline and Cycle One Efficacy Data from ANCHOR-CD: A Multicenter, Observational Study of Abobotulinumtoxin a in Cervical Dystonia
  Espay AJ, Comella CL, Truong DD, LeWitt PA, Chen JJ, Marchese D, Abbott C, Cetnarowski W, Trosch RM., Mov Disord, 1/1/2014
• SCA 17 Phenotype with Borderline Triplet Repeat Number
  Herrema H, Mikkelson T, Robin A, LeWitt PA, Sidiropoulos C, Mov Disord, 1/1/2014
• ANCHOR-CD. AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cerv...
  Trosch RM, Jozefczyk PB, Truong D, Lew MF, Adler CH, LeWitt PA, Singer C, Castagna AM, Betts G, Abbott C, Marchese D, Comella CL, Neurology, 1/1/2013
• Double-blind Study of an Actively-transported Levodopa Prodrug, XP21279, in Parkinson Disease
  LeWitt PA, Huff FJ, Hauser R, Chen D, Lissin D, Cundy K., Neurology, 1/1/2013
• Test-retest Reliability of a Parkinson's Disease Monitoring System
  Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP, Neurology, 1/1/2013
• Intraoperative MRI for Deep Brain Stimulation Electrode Positioning in Parkinson's Disease
  Sidiropoulos C, LeWitt PA, Taylor D, Kaminski P, Scarpace L, Gorham J, Schwalb J, Mov Disord, 1/1/2013
• Constant Therapeutic Levodopa (LD) Plasma Concentrations Maintained by Continuous Subcutaneous (SC) Administration of ND-0612, a Novel Formulation of LD/Carbidopa (CD).
  Caraco Y, Oren S, LeWitt P, Mov Disord, 1/1/2013
• Sustained-release Carbidopa-levodopa (Accordian Pill) In Patients with Advanced Parkinson's Disease: Pharmacokinetic and Clinical Experience
  LeWitt P, Friedman H, Giladi N, Gurevich T, Shabtai H, Djaldetti R, Roizen N, Hassin-Baer S, Cohen O, Yahalom G, Schlessinger I, Nassar M, Milo R, Anka M, Farkas P, Na..., Mov Disord, 1/1/2013
• Test-retest Reliability of a Parkinson's Disease Monitoring System
  Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP, Mov Disord, 1/1/2013
• Acoustic Analysis of Voice in Parkinson's Disease and Amyotrophic Lateral Sclerosis
  Silbergleit AK, LeWitt PA, Gardner G, Petersin E, Mov Disord, 1/1/2013
• ANCHOR-CD (AbobotulinumtoxinA Neurotoxin Clinical and Health Economics Outcomes Registry in Cervical Dystonia): Baseline Data and Cycle One Efficacy Data
  Trosch R, Jozefczyk P, Truong D, Lew M, Adler C, LeWitt P, Singer C, Silay Y, Castagna A, Marchese D, Cetnarowski W, Comella C., Mov Disord, 1/1/2013
• Reliability of The Essential Tremor Rating Assessment Scale (TETRAS).
  Elble R, LeWitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Zesiewicz T., Mov Disord, 1/1/2012
• Inter-rater Reliability of the Essential Tremor Rating Assessment Scale (TETRAS).
  Elble R, LeWitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Zesiewicz T., Neurology, 1/1/2012
• Accordion Pill Carbidopa/Levodopa for Improved Treatment of Advanced Parkinson's Disease Symptoms
  LeWitt PA, Friedman H, Giladi N, Gurevich T, Shabtai H, Djaldetti R, Roizen N, Hassin-Baer S, Cohen O, Gilad Y, Schlessinger I, Nassar M, Milo R, Navon N., Mov Disord, 1/1/2012
• Bilateral Thalamic Vim DBS for Orthostatic Tremor: New Insights and Literature Review
  Sidiropoulos C, LeWitt PA, Schwalb JM, Mov Disord, 1/1/2012
• Analysis of Efficacy and Safety Outcomes in Patients Treated with Droxidopa in Combination with Other Drug Classes
  LeWitt P, Gorny S, Mov Disord, 1/1/2012
• Novel Biomarkers of Parkinson's Disease: CSF Concentrations of Xanthine, Homovanillic Acid, and Their Ratio
  LeWitt PA, Schultz L, Auinger P, Parkinson Study Group DATATOP Investigators, Mov Disord, 1/1/2011
• PD Biomarker Search: Metabolomic Analysis of Post-mortem CSF
  LeWitt PA, Lu M, Poisson L, Beach T, Adler C, Guo L, Mov Disord, 1/1/2011
• Administration of Continuous Subcutaneous Carbidopa Improves Levodopa Pharmacokinetics
  Yacoby-Zeevi O, Oren S, LeWitt P, Mov Disord, 1/1/2011
• Actively-transported Levodopa Prodrug XP21279: A Study in Parkinson's Disease Subjects Experiencing Motor Fluctuations
  LeWitt P, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ, Mov Disord, 1/1/2011
• Abnormal Apocrine Sweat Gland Mitochondria in Huntington's Disease
  Sidiropoulos C, LeWitt P, Hashimoto K., Mov Disord, 1/1/2011
• Long-term Treatment of Advanced Parkinson's Disease with Rotigotine
  LeWitt PA, Boroojerdi B, Poewe W, SP 516 and SP 715 Study Groups, Neurology, 1/1/2010
• Join now to see all